Talphera Appoints Joe Todisco to Board Amid CorMedix Partnership and Niyad™ Development

Talphera Welcomes New Board Member Amid Strategic Partnership with CorMedix

Talphera, Inc., a San Mateo-based specialty pharmaceutical company, announces the appointment of Joe Todisco, CEO of CorMedix Inc., to its Board of Directors. This strategic move occurs in the context of a recent private placement financing, where CorMedix invested in Talphera, allowing them to nominate a representative on the board. The partnership is particularly significant as it comes with exclusive negotiation rights for CorMedix to finalize an acquisition agreement with Talphera, contingent on the successful outcomes from the NEPHRO CRRT clinical study. This collaboration highlights the potential for growth and innovation within Talphera as it navigates the complexities of drug development in the competitive pharmaceutical landscape.

The NEPHRO CRRT study focuses on Talphera's lead product, Niyad™, a lyophilized formulation of nafamostat, which is being investigated as an anticoagulant for extracorporeal circuits. Niyad™ has received Breakthrough Device Designation from the FDA, signaling its potential significance in improving patient outcomes. Adrian Adams, Chairman of Talphera’s Board, praises Todisco’s extensive experience in pharmaceutical commercialization and product expansion, indicating that his expertise could be vital as Talphera seeks to bring Niyad™ to market. With the registrational study expected to yield results that could influence regulatory approval by 2026, the company is optimistic about Niyad™ setting a new standard of care in medically supervised settings.

The collaboration with CorMedix not only strengthens Talphera's financial footing but also aligns its strategic objectives with a partner that shares a commitment to developing innovative therapies. The exclusive negotiation period allows Talphera to focus on advancing its clinical studies without the immediate pressures of outside financing or acquisitions, fostering a conducive environment for potential breakthroughs. As Talphera prepares for the next stages of its product development, the integration of Todisco into the board marks a significant step towards enhancing its operational capabilities and strategic vision.

In addition to this board appointment, Talphera continues to emphasize its commitment to developing therapies that address critical medical needs. The collaboration with CorMedix is expected to leverage both companies' strengths, propelling Talphera's growth trajectory in the specialty pharmaceutical sector. With Niyad™ at the forefront of its research efforts, Talphera remains focused on delivering innovative solutions that could redefine care in renal replacement therapy.

For more details about Talphera’s initiatives and product developments, visit their official website at www.talphera.com.